Year: 2015

A recent study conducted at Tampa General Hospital in Florida, and published in the Journal of Clinical Microbiology, tested the use of ESwab™ with the BD Max MRSAXT and BD Max StaphSR assays. The study, consisting of 255 samples collected using ESwab™ showed that the assays have exceptional sensitivity and specificity for detecting MRSA and S. aureus, respectively

This agreement allows bioMérieux to speed up deployment of its “FMLA^® Lab Efficiency*” vision for the automation and enhanced operational efficiency of clinical microbiology labs. In this field, the two companies also plan to collaborate in particular for the development of innovative clinical microbiology diagnostic solutions.

Colibri™ is an open platform capable of utilizing a diversity of consumables from different suppliers or prepared in house. In keeping with the philosophy of developing open platforms, Colibri™ can work in-line with WASPLab™ or as a standalone workstation to automatically prepare AST and ID suspensions and seed MALDI-TOF target plates with more functionality to come.

COPAN Diagnostics, a company committed to new innovations and education in the field of preanalytics, launches a newly redesigned website. The website Copanusa.com aims to improve COPAN’s online brand and features various enhancements visitors to the site will enjoy.

FecalSwab™ simplifies and standardizes fecal sample collection, transport and processing by converting solid or semi-solid fecal specimens into a phase suitable for fully automatic specimen processors, in space saving, instrument ready tubes. FecalSwab™ provides a compact and neat alternative to traditional large, bulky transport containers, which collect a quantity far greater than needed for culture or molecular testing.

Notably these two new US patents, US 8,979,784 and US 9,011,358, have a broad scope of protection for the flocked swab device, in addition to the method of use of such device previously covered by the first two US patents. COPAN is in a strong position to legally stop any infringing activity, such as manufacturing, promoting and selling, including exporting from the US to other countries, flocked swabs covered by the patent claims.